Investigating new treatments for Alzheimer's disease using diabetes medications and natural compounds.
Official title: Comparison of Tirzepatide, Retatrutide, and Crocetin, for Mitigation of Alzheimer's-like Pathology in a Mouse Model of Alzheimer’s Disease
Funded at Nova Southeastern University · NIH-11043894 · Data updated 2026-11-12
This study is looking at how new diabetes medications and a natural compound might help improve memory and brain health in mice that show signs of Alzheimer's, with the hope of finding better treatments for both diabetes and Alzheimer's disease.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nova Southeastern University NIH-funded |
| Lab location | 1 site (Fort Lauderdale-Davie, UNITED STATES) |
| Project start | December 15, 2024 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $372,400 |
| NIH project number | 1R15AG091199-01 |
| Project ID | NIH-11043894 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are experiencing cognitive decline or have a diagnosis related to Alzheimer's disease.
✕Less likely to help
Patients who are younger than 65 or do not have any cognitive impairment or Alzheimer's-related conditions may not benefit from this research.
What this research studies
This research explores the potential of new diabetes medications, tirzepatide and retatrutide, along with a natural compound called crocetin, to reduce Alzheimer's-like symptoms in a mouse model. The study aims to understand how these treatments can modify the underlying disease processes rather than just alleviate symptoms. By examining their effects on cognitive decline and neuroprotection, the research seeks to identify promising new therapies for Alzheimer's disease. The findings could lead to innovative treatment options that address both diabetes and Alzheimer's pathology.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that not only treat Alzheimer's disease but also improve cognitive function in patients with diabetes.
How similar studies have gone: Previous research has shown that certain diabetes medications can have neuroprotective effects, indicating a promising avenue for further exploration in Alzheimer's treatment.
Where this research is happening
-
Nova Southeastern University
Fort Lauderdale-Davie, United States Active
Researchers
- Principal investigator: Speth, Robert Charles — Nova Southeastern University
- Study coordinator: Speth, Robert Charles
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.